Nanoviricides (NNVC) Cash from Investing Activities Growth (3y) (2013 - 2024)
Nanoviricides (NNVC) Cash from Investing Activities Growth (3y) (2013 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -44.69% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -39.73% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -246.81% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -177.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.84% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -53.57% |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 26.09% |
| Jun 30, 2016 | 7.08% |
| Jun 30, 2015 | -10,514.64% |
| Mar 31, 2015 | 309.84% |
| Dec 31, 2014 | -538.42% |
| Sep 30, 2014 | -168.42% |
| Jun 30, 2014 | -197.49% |
| Mar 31, 2014 | -221.42% |
| Dec 31, 2013 | -116.15% |
| Sep 30, 2013 | -197.38% |